Zacks Investment Research
23 Jun 2026, 15:55 UTC · 20w ago
Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals
Impact · against what's priced in
Definium Therapeutics (DFTX) is a strong buy following positive Phase III results for DT120 in major depressive disorder. The achievement of primary and secondary endpoints for a single-dose psychedelic therapy provides a clear path toward FDA approval and market disruption.
- DFTX+0.80
No priced-in read yet
- In context
The Phase III Emerge study met its primary and all key secondary efficacy endpoints for DT120, demonstrating rapid and durable improvements in depressive symptoms after a single 100 μg dose.
Read from the article alone
Search tags
